PMN

Promis Neuroscie

• TipRanks·03/26 18:05

  ProMIS Neurosciences: Strengthened Balance Sheet and Differentiated PMN310 Alzheimer’s Program Underpin Buy Rating

• NASDAQ·03/26 13:42

  ProMIS Slides To FY25 Net Loss; Expects Interim Data From Phase 1b Trial Of PMN310 In Early Q3 2026

• Seeking Alpha·03/26 13:23

  Promis Neurosciences files $200M multi-security shelf offering

• Benzinga·03/25 21:25

  ProMIS Neurosciences Files Prospectus To Offer Securities Up To $200M

• TipRanks·03/25 21:25

  ProMIS Neurosciences files $200M mixed securities shelf

• Reuters·03/25 21:23

  PROMIS NEUROSCIENCES INC - MAY OFFER UP TO $50 MLN COMMON SHARES UNDER SALES AGREEMENT - SEC FILING

• Reuters·03/25 21:23

  PROMIS NEUROSCIENCES INC - MAY OFFER SECURITIES UP TO $200 MLN - SEC FILING

• Benzinga·03/25 12:05

  ProMIS Neurosciences Q4 EPS $(21.83) Misses $(0.21) Estimate

• Seeking Alpha·03/25 12:03

  ProMIS Neurosciences GAAP EPS of -$22.61 misses by $2.57

• Reuters·03/25 12:03

  ProMIS Neurosciences FY2025 net loss rises to $40 million; R&D expenses more than tripled to $33 million

• Dow Jones·03/25 12:01

  *ProMIS Neurosciences 2025 Loss/Shr $22.61 >PMN

• Dow Jones·03/25 12:01

  *ProMIS Neurosciences 2025 Research and Development Expenses $33.4M >PMN

• Reuters·03/25 12:00

  PROMIS NEUROSCIENCES ANNOUNCES FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE HIGHLIGHTS

• TipRanks·03/18 20:21

  ProMIS Neurosciences files to sell 13.83M common shares for holders

• Benzinga·03/18 12:03

  ProMIS Neurosciences To Highlight Data On ALS & Parkinsons Disease Programs At AD/PD 2026 International Conference